Add like
Add dislike
Add to saved papers

Evaluation of thyroid FDG uptake incidentally identified on FDG-PET/CT imaging.

OBJECTIVES: To characterize the prevalence and malignancy of thyroid F-flurodeoxyglucose (FDG) uptake incidentally identified on FDG-PET/computed tomography (CT) scan in a relatively large population.

METHODS: Two thousand five hundred and ninety-four cases of FDG-PET/CT performed at our institute in the past 1 year and a half were retrospectively reviewed. Images with incidental focal or diffuse thyroid FDG uptake were identified. Data of the PET findings, thyroid functional assay, and pathological diagnosis were collected and analyzed. Incidental thyroid FDG uptake was defined as a new thyroid lesion initially identified on PET scan in a patient without a previous known history of thyroid disease.

RESULTS: The prevalence of incidental thyroid FDG uptake (including both focal and diffuse lesions) was 3.8% (99 of 2594) on FDG-PET/CT, of which 1.8% (46 of 2594) were diffuse and 2.0% (53/2594) were focal. Of the 46 cases with diffuse uptake, 21 had thyroid functional assay and/or ultrasound study, and a diagnosis of chronic thyroiditis was made in all of the 21 cases. Eleven of the 53 patients with focal uptake had fine-needle aspiration or postsurgical pathological diagnosis, four benign lesions (four of 11=36.4%: two thyroid adenomas and two hyperplastic lesions); seven malignancies (seven of 11=63.6%: three papillary carcinomas, two follicular carcinoma, and two metastases). There was overlapping of the lesion SUVmax between the benign and malignant cases, with no statistical difference of the mean SUVmax between the two groups.

CONCLUSION: Thyroid FDG uptake incidentally identified on FDG-PET/CT occurred at a frequency of 3.8%, with about half of focal and half of diffuse lesions. The risk of thyroid malignancy was 63.6% in lesions with focal uptake, whereas the majority of diffuse uptake cases represents chronic thyroiditis. More data are needed to elucidate the role of SUV in the differentiation of benign and malignant lesions.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app